We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Valneva’s single-shot chikungunya vaccine candidate, VLA1553, has seen positive topline results from its Phase III pivotal trial. VLA1553 was recently awarded breakthrough designation status by the Food and Drug Administration (FDA).
French speciality vaccine company Valneva has announced that its single-shot chikungunya vaccine candidate has received a breakthrough therapy designation from the US Food and Drug Administration (FDA).
ValnevaSE announced today it will host a virtual symposium titled, "Developing new vaccines to protect against infectious diseases at home and abroad" on July 9, at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)